These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31535639)

  • 1. Highlights of ASS234: a novel and promising therapeutic agent for Alzheimer's disease therapy.
    Romero A; Marco-Contelles J; Ramos E
    Neural Regen Res; 2020 Jan; 15(1):30-35. PubMed ID: 31535639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic and structural analysis of the irreversible inhibition of human monoamine oxidases by ASS234, a multi-target compound designed for use in Alzheimer's disease.
    Esteban G; Allan J; Samadi A; Mattevi A; Unzeta M; Marco-Contelles J; Binda C; Ramsay RR
    Biochim Biophys Acta; 2014 Jun; 1844(6):1104-10. PubMed ID: 24642166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The proof-of-concept of ASS234: Peripherally administered ASS234 enters the central nervous system and reduces pathology in a male mouse model of Alzheimer disease.
    Serrano MP; Herrero-Labrador R; Futch HS; Serrano J; Romero A; Fernandez AP; Samadi A; Unzeta M; Marco-Contelles J; Martínez-Murillo R
    J Psychiatry Neurosci; 2017 Jan; 42(1):59-69. PubMed ID: 27636528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.
    Unzeta M; Esteban G; Bolea I; Fogel WA; Ramsay RR; Youdim MB; Tipton KF; Marco-Contelles J
    Front Neurosci; 2016; 10():205. PubMed ID: 27252617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
    Bolea I; Juárez-Jiménez J; de Los Ríos C; Chioua M; Pouplana R; Luque FJ; Unzeta M; Marco-Contelles J; Samadi A
    J Med Chem; 2011 Dec; 54(24):8251-70. PubMed ID: 22023459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ASS234, As a New Multi-Target Directed Propargylamine for Alzheimer's Disease Therapy.
    Marco-Contelles J; Unzeta M; Bolea I; Esteban G; Ramsay RR; Romero A; Martínez-Murillo R; Carreiras MC; Ismaili L
    Front Neurosci; 2016; 10():294. PubMed ID: 27445665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
    Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J
    Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor.
    Bautista-Aguilera OM; Samadi A; Chioua M; Nikolic K; Filipic S; Agbaba D; Soriano E; de Andrés L; Rodríguez-Franco MI; Alcaro S; Ramsay RR; Ortuso F; Yañez M; Marco-Contelles J
    J Med Chem; 2014 Dec; 57(24):10455-63. PubMed ID: 25418133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multipotent, permeable drug ASS234 inhibits Aβ aggregation, possesses antioxidant properties and protects from Aβ-induced apoptosis in vitro.
    Bolea I; Gella A; Monjas L; Pérez C; Rodríguez-Franco MI; Marco-Contelles J; Samadi A; Unzeta M
    Curr Alzheimer Res; 2013 Oct; 10(8):797-808. PubMed ID: 23919774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroinflammation Signaling Modulated by ASS234, a Multitarget Small Molecule for Alzheimer's Disease Therapy.
    Del Pino J; Marco-Contelles J; López-Muñoz F; Romero A; Ramos E
    ACS Chem Neurosci; 2018 Dec; 9(12):2880-2885. PubMed ID: 30048111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro and in-vivo evaluation of the modulatory effects of the multitarget compound ASS234 on the monoaminergic system.
    Esteban G; Van Schoors J; Sun P; Van Eeckhaut A; Marco-Contelles J; Smolders I; Unzeta M
    J Pharm Pharmacol; 2017 Mar; 69(3):314-324. PubMed ID: 28134992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
    Wang L; Esteban G; Ojima M; Bautista-Aguilera OM; Inokuchi T; Moraleda I; Iriepa I; Samadi A; Youdim MB; Romero A; Soriano E; Herrero R; Fernández Fernández AP; Ricardo-Martínez-Murillo ; Marco-Contelles J; Unzeta M
    Eur J Med Chem; 2014 Jun; 80():543-61. PubMed ID: 24813882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
    Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS
    Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of novel monoamine oxidases and cholinesterases targeting compounds on brain neurotransmitters and behavior in rat model of vascular dementia.
    Stasiak A; Mussur M; Unzeta M; Samadi A; Marco-Contelles JL; Fogel WA
    Curr Pharm Des; 2014; 20(2):161-71. PubMed ID: 23701539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
    Bautista-Aguilera OM; Esteban G; Chioua M; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Soriano E; Samadi A; Unzeta M; Marco-Contelles J
    Drug Des Devel Ther; 2014; 8():1893-910. PubMed ID: 25378907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells.
    Liu W; Rabinovich A; Nash Y; Frenkel D; Wang Y; Youdim MBH; Weinreb O
    Neuropharmacology; 2017 Feb; 113(Pt A):445-456. PubMed ID: 27984078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Heat Shock Response Proteins by ASS234, Targeted for Neurodegenerative Diseases Therapy.
    Ramos E; Romero A; Marco-Contelles J; López-Muñoz F; Del Pino J
    Chem Res Toxicol; 2018 Sep; 31(9):839-842. PubMed ID: 30133257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil-butylated hydroxytoluene (BHT) hybrids as Anti-Alzheimer's disease agents with cholinergic, antioxidant, and neuroprotective properties.
    Cai P; Fang SQ; Yang HL; Yang XL; Liu QH; Kong LY; Wang XB
    Eur J Med Chem; 2018 Sep; 157():161-176. PubMed ID: 30096650
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Więckowska A; Szałaj N; Góral I; Bucki A; Latacz G; Kiec-Kononowicz K; Bautista-Aguilera ÒM; Romero A; Ramos E; Egea J; Farré Alíns V; González-Rodríguez Á; López-Muñoz F; Chioua M; Marco-Contelles J
    ACS Chem Neurosci; 2020 Nov; 11(22):3793-3801. PubMed ID: 33143412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease.
    Samadi A; Chioua M; Bolea I; de Los Ríos C; Iriepa I; Moraleda I; Bastida A; Esteban G; Unzeta M; Gálvez E; Marco-Contelles J
    Eur J Med Chem; 2011 Sep; 46(9):4665-8. PubMed ID: 21669479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.